Volition Signs First Commercial Project Utilizing Rapid High-Throughput Model in the Study of NETosis

Rhea-AI Summary

VolitionRx (NYSE AMERICAN: VNRX) has announced its first commercial sale of their High Throughput Synthetic Sepsis method, a breakthrough technology that measures Neutrophil Extracellular Traps (NETs) activation and inhibition in whole blood in real time. This innovative approach helps companies develop new therapeutics for sepsis and NETs-related diseases.

The technology addresses significant limitations in previous research by measuring NETs directly in whole blood, avoiding potential alterations in neutrophil responses caused by isolation procedures. The method provides a more physiologically relevant environment for studying neutrophil responses and enables precise measurement of NETs formation.

Sepsis, responsible for approximately 370,000 US deaths annually, involves NETs which are essential for trapping and neutralizing pathogens. However, their overproduction can lead to tissue damage and disease progression. This new technology aims to enhance understanding of conditions characterized by uncontrolled NETs formation and serve as a key tool in translational research.

Positive

• First commercial sale of High Throughput Synthetic Sepsis method
• Technology addresses major research limitations in NETs measurement
• Enables real-time monitoring of NETs in whole blood
• Potential for new therapeutic developments in sepsis treatment

Negative

• None.

Expanding commercial offering as a bio-partnering model, currently in active discussions with pharmaceutical companies 

HENDERSON, Nev., Feb. 6, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) Volition a multi-national epigenetics company, announces its first commercial sale of Volition's High Throughput Synthetic Sepsis method that measures Neutrophil Extracellular Traps "NETs" activation and inhibition in whole blood in real time, helping companies develop new therapeutics to combat sepsis and other NETs-related disease.

Dr. Jasmine Kway, CEO of Singapore Volition and Commercial Lead for Nu.Q® Discover said:

"Our High Throughput NETs model represents a critical breakthrough in understanding neutrophil biology; A fundamental understanding of NETs-related diseases in vivo has been challenging to date."

"Most studies rely on isolated primary neutrophils, which miss many potential crosstalk events which happen in whole blood. By enabling more precise measurement of NETs formation, we're opening new pathways for therapeutic interventions in NETs-related diseases."

Key Highlights of Rapid High-Throughput Model

-        Method to quantitatively monitor NETs release in real time
-        Eliminates neutrophil isolation steps that can alter cellular responses
-        Builds on foundational research published in the Journal of Thrombosis and Hemostasis
-        Provides a more physiologically relevant environment for studying neutrophil responses

Dr. Terry Kelly, Chief Innovation Officer at Volition America, added:

"This marks the culmination of the last two years of work demonstrating the ability to induce and inhibit NETs formation in healthy blood using an automated high throughput system. There is an increasing trend of published scientific literature about NETs as scientists and biopharmaceutical companies race to develop new interventions based on an improved understanding of the underlying biology and mechanisms at play."

Volition's innovative approach addresses a significant technical limitation in previous research. By measuring NETs directly in whole blood, the method avoids potential alterations in neutrophil responses caused by isolation procedures, as highlighted by recent commentary in JTH.

"This technology has the potential to unlock new understanding of conditions characterized by uncontrolled NETs formation and can serve as a key tool in translational research and the study of NETosis related disease."

Sepsis, NETs and NETosis

Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection It is responsible for ~370,000 US deaths annually. Neutrophils are an integral part of the innate immune response and rapidly clear pathogens from circulation using neutrophil extracellular traps (NETs) released through a process called NETosis.

NETs have become more relevant in disease but have not been widely characterized in humans. NETs are essential for trapping and neutralizing pathogens, but overproduction or uncontrolled formation (NETosis) can lead to tissue damage and disease progression during the inflammatory response.

Studies in NETosis have been mostly limited to isolated systems with unnatural stimulation. However, understanding natural NETosis activation and the underlying mechanisms could lead to new biomarkers and understanding of how these neutrophil associated diseases are regulated in vivo.

Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases in both humans and animals.

For more information about Volition's technology go to: www.volition.com

About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential not only to prolong the life of patients but also improve their quality of life.

Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and additional offices in London and Singapore.

The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document.  Such website address is included in this document as an inactive textual reference only.

Media Enquiries:

Louise Batchelor, Volition, mediarelations@volition.com, +44 (0)7557 774620

Investor Relations
Jeremy Feffer, LifeSci Advisors, jfeffer@lifesciadvisors.com, +1-212-915-2568

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the timing, completion, success and delivery of data from clinical studies, the timing of publications, , the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and Volition's success in securing licensing and/or distribution agreements with third parties for its products. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this press release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics™, Capture-PCR™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

View original content:https://www.prnewswire.com/news-releases/volition-signs-first-commercial-project-utilizing-rapid-high-throughput-model-in-the-study-of-netosis-302370192.html

SOURCE VolitionRx Limited

FAQ

What is the significance of VNRX's new High Throughput Synthetic Sepsis method?

The method enables real-time measurement of NETs activation and inhibition in whole blood, providing a more accurate way to study neutrophil responses and develop new therapeutics for sepsis and NETs-related diseases.

How does VNRX's new NETs measurement technology differ from traditional methods?

Unlike traditional methods that use isolated neutrophils, VNRX's technology measures NETs directly in whole blood, avoiding potential alterations in cellular responses and providing a more physiologically relevant environment.

What market opportunity does VNRX's NETs technology address?

The technology addresses the sepsis market, which accounts for approximately 370,000 US deaths annually, and offers potential applications in studying and treating various NETs-related diseases.

What are the key features of VNRX's Rapid High-Throughput Model?

The model quantitatively monitors NETs release in real time, eliminates neutrophil isolation steps, and builds on research published in the Journal of Thrombosis and Hemostasis.

How could VNRX's NETs technology impact drug development?

The technology could accelerate therapeutic development by providing better understanding of NETs-related diseases and enabling more accurate testing of potential treatments in whole blood conditions.